Lonza, WuXi Biologics & CDMO Global Market: Competitive Landscape Evolution
Executive at AGC Biologics
inpractise.com/articles/lonza-wuxi-biologics-and-cdmo-global-market-competitive-landscape-evolution
Executive at AGC Biologics
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Do you see any particular drug category having a larger shift from China to other countries?
The major reason why it's enough to look at WuXi is that this company is a main driver and one of the most established CDMOs in China, with FDA approval, EMA approval, and high-quality standards. Therefore, a lot of Western customers ended up at WuXi for slightly cheaper prices, more flexible conditions, and ultimately good quality and timely deliveries. WuXi was a high-quality player offering very reasonable terms and conditions, attracting many Western customers who now need to look for new homes.
This is a snippet of the transcript, sign up to read more.
Related Content
Lonza: CDMO Market Capacity
Executive at AGC Biologics
Lifecore Biomedical: Customer Mix, Switching Cost & Power in the CDMO Value Chain
Former Senior VP at Lifecore Biomedical
Maravai LifeSciencies: Trilink Biotech
Principal Scientist at Moderna
MaxCyte: Electroporation Technology, Cell & Gene Therapy & Competition
Former Business Development Technical Expert at MaxCyte
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.